ArticleWorld journal of oncology2025
Prognostic Significance of Post-Neoadjuvant Chemotherapy Carbohydrate Antigen 19-9 Levels in Patients With Resectable Pancreatic Cancer Treated With S-1 and Gemcitabine: A Retrospective Cohort Study.
Article in World journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbohydrate antigen 19-9 (CA19-9) is widely used to assess treatment response and monitor recurrence alongside imaging. However, the criteria for determining resectability after completion of neoadjuvant therapy (NAT) remain poorly defined. Therefore, this study aimed to investigate the indications for surgical resection as a prognostic factor following NAT with gemcitabine and S-1 (NATGS). Methods: In this retrospective cohort study, we examined patients who underwent curative pancreatic resection following NATGS at our institution between April 2018 and December 2023. After excluding six patients who did not undergo pancreatectomy, the remaining 50 patients were included in the study. Univariate and multivariate analyses were conducted to identify factors potentially associated with survival after NATGS. Results: Post-NATGS CA19-9 levels (< 100 U/mL) were identified as a significant prognostic factor for disease-free survival (DFS) in both univariate and multivariate analyses (hazard ratio (HR) = 11.72251, P < 0.001). For overall survival (OS), both CA19-9 levels (< 100 U/mL) and Duke pancreatic monoclonal antigen type 2 (DUPAN-2) levels (< 150 U/mL) were significant prognostic factors in univariate and multivariate analyses (CA19-9: HR = 17.88, P = 0.002; DUPAN-2: HR = 2.667, P = 0.03). The median DFS was 24.1 months in the low CA19-9 group compared with the 7.1 months in the high CA19-9 group (P = 0.002). The median OS in the low CA19-9 group was not reached, whereas it was 14.7 months in the high CA19-9 group (P = 0.001). Conclusions: The CA19-9 cut-off value is clinically significant for patients undergoing NATGS regimens. Patients with pre-operative CA19-9 levels ≥ 100 U/mL may benefit from extended GS treatment or a switch to a more potent regimen rather than proceeding directly to surgical resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.